What is CELC stock price today?

CELC (Celcuity Inc) stock is trading at $125.25 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CELC stock going up or down today?

CELC stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CELC stock now?

The decision to buy CELC depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CELC a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CELC based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CELC stock overvalued or undervalued?

Use our DCF valuation calculator to determine if CELC is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is CELC's P/E ratio?

P/E ratio data for CELC will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is CELC's market cap?

CELC (Celcuity Inc) has a market capitalization of $5.97 billion, making it a small-cap stock.

What is CELC's price to book ratio?

CELC trades at a price-to-book (P/B) ratio of 59.35, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CELC pay dividends?

CELC does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CELC's dividend yield?

CELC does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CELC stock a good long-term investment?

CELC's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CELC's revenue growth rate?

Revenue growth data for CELC is available on our dashboard with detailed financial statement analysis.

Profitability metrics for CELC are available on our dashboard with complete income statement analysis.

What are the risks of investing in CELC?

Key risks for CELC include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CELC compare to its competitors?

Compare CELC to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CELC's performance and positioning.

What is CELC's stock price target for 2026?

Our AI model provides price targets for CELC based on fundamental analysis: Bull case $162.83 (+30%), Base case $144.04 (+15%), Bear case $112.73 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CELC?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CELC. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CELC's next earnings report?

CELC reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CELC - Celcuity Inc

NYSE * Health Care * Biotechnology

$125.25

+$1.78 (+1.44%)

About Celcuity Inc

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

CELC Key Statistics

Market Cap

$5.97B

P/B Ratio

59.35

EPS

$-3.79

Employees

155

How CELC Compares to Peers

CELC is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CELC(This stock)	$5.97B	N/A	0%	0.0%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Celcuity Inc Company Information

Headquarters: Minnesota; U.S.A
Website: www.celcuity.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 17, 2026 at 7:17 AM EDT

Ready to invest in CELC?

Commission-free trading available. Affiliate links.

CELC Lician Score

5% confidence

4.0/10

Neutral

CELC has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates CELCacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

CELC Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for CELC

Dashboard

Enter a ticker to analyze